Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience

Sarah Raevens1, Xavier Rogiers2,3, Anja Geerts1, Xavier Verhelst1, Undine Samuel3, Marieke van Rosmalen3, Gabriela Berlakovich4, Jean Delwaide5, Olivier Detry6, Frank Lehner7, Jens Mittler8, Silvio Nadalin9, Frederik Nevens10, Jacques Pirenne11, Fuat Saner12, Stefan Schneeberger13, Dirk Stippel14, Jerovšek Marjana Turk15, Mathe Zoltan16, Roberto Ivan Troisi2,17, Hans Van Vlierbergh1 and Isabelle Colle1

Affiliations: 1Dept of Gastroenterology and Hepatology, Ghent University Hospital, Ghent University, Ghent, Belgium. 2Dept of General, Hepatobiliary and Liver Transplantation Surgery, Ghent University Hospital, Ghent University, Ghent, Belgium. 3Eurotransplant, Leiden, The Netherlands. 4Division of Transplantation, Dept of Surgery, Medical University of Vienna, Vienna, Austria. 5Dept of Gastroenterology and Hepatology, CHU Liège, University of Liège, Liège, Belgium. 6Dept of Abdominal Surgery and Transplantation, CHU Liège, University of Liège, Liège, Belgium. 7General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany. 8 Dept of General, Visceral, and Transplant Surgery, University Medical Center Mainz, Mainz, Germany. 9Dept of General, Visceral and Transplant Surgery, University Hospital Tubingen, Tubingen, Germany. 10Dept of Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium. 11Abdominal Transplant Surgery, University Hospitals KU Leuven, Leuven, Belgium. 12Dept of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany. 13Dept of Visceral Transplant and Thoracic Surgery, Medical University Innsbruck, Innsbruck, Austria. 14Division of Transplant Surgery, Dept of General, Visceral and Cancer Surgery, Transplant Center Cologne, University of Cologne, Cologne, Germany. 15Dept of Gastroenterology and Hepatology, University Medical Center Ljubljana, Ljubljana, Slovenia. 16Dept of Transplantation and Surgery, Semmelweis University Budapest, Budapest, Hungary. 17Dept of Clinical Medicine and Surgery, Federico II University Naples, Naples, Italy.

Correspondence: Sarah Raevens, Dept of Gastroenterology and Hepatology, Ghent University Hospital, Building K12, First Floor IE, Corneel Heymanslaan 10, 9000 Ghent, Belgium. E-mail: sarah.raevens@ugent.be

To the Editor:

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar–arterial oxygen gradients with no hypoxaemia to very severe hypoxaemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-month waiting list mortality and is used by Eurotransplant for prioritising allocation of liver transplants [4]. However, this score poorly predicts overall and post-transplant survival, and does not take into account complications that affect outcomes independent of liver disease severity.
Hypoxaemia in HPS is generally progressive and mortality is highest in advanced stages [6, 7]. In this sense, a standard exception (SE) policy has been established to prioritise patients with severe HPS (arterial oxygen tension (PaO₂) <60 mmHg), as their severity of illness is not properly reflected by the MELD score. In the pre-SE MELD era, Fallon et al. [1] reported that HPS is associated with a doubled risk of mortality compared to patients without HPS. In 2014, Goldberg et al. [5] reviewed SE LT outcomes in HPS patients in the USA and found that LT candidates with SE for HPS had decreased pre-transplantation mortality and superior overall survival compared to non-HPS patients. The European outcomes for patients with SE for HPS have never been explored. In this retrospective study, we analysed overall, pre-transplant and post-transplant survival in LT candidates with SE for HPS within Eurotransplant, and determined whether the intent of the exception policy is being met.